With the intensifying investigation of antiangiogenic therapies, research targeting ANGPTL4 may offer a strategy with great potential in future drug development to reduce the tumor burden and to improve therapeutic efficacy in ovarian cancer. The gene discussed is ANGPTL4; the disease is ovarian carcinoma.